Glaucoma
Conditions
Brief summary
The effect of latanoprost with preservatives on the ocular surface microbiome
Detailed description
Evidence suggests that the ocular surface microbiome of patients using preserved glaucoma eye drops differs from that of healthy individuals. These microbial changes have been linked to both the glaucoma treatment itself and the presence of preservatives, particularly benzalkonium chloride (BAK), in the eye drops. However, existing studies have primarily assessed these differences by comparing treated glaucoma patients to healthy controls, rather than examining changes within the same individuals over time. The aim of this study is to evaluate how glaucoma medications containing the preservative benzalkonium chloride affect the ocular surface microbiome in the same patients before and after the initiation of therapy.
Interventions
DRUGLatanoprost with preservatives (BAK) once per day for at least 6 months period
Existing studies have primarily assessed these differences by comparing treated glaucoma patients to healthy controls, rather than examining changes within the same individuals over time.
Sponsors
University of Ioannina
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Newly diagnosed treatment naive glaucoma patients or those with ocular hypertension
Exclusion criteria
* Patients' history of recent ocular surgery or trauma, * Patient with any type of conjunctivitis and ocular surface inflammation recent to the time of diagnosis * Patients using topical antibiotics * Contact lenses wearers * Patients in other chronic treatments with eye drops
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in ocular microbiome | 6 months | Alpha and beta diversity before and at least 6 months after the treatment |
Countries
Greece
Outcome results
None listed